Share-based Payment Arrangement, Expense of Galera Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Galera Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Galera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $91,000, a 83% decline year-over-year.
  • Galera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $714,000, a 79% decline year-over-year.
  • Galera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,545,000, a 54% decline from 2023.
  • Galera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,560,000, a 22% decline from 2022.
  • Galera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,164,000, a 0.93% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Galera Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $714,000 $91,000 -$460,000 -83% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $1,174,000 $90,000 -$633,000 -88% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $1,807,000 $137,000 -$738,000 -84% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $2,545,000 $396,000 -$791,000 -67% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $3,336,000 $551,000 -$839,000 -60% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $4,175,000 $723,000 -$802,000 -53% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $4,977,000 $875,000 -$583,000 -40% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $5,560,000 $1,187,000 -$549,000 -32% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $6,109,000 $1,390,000 -$360,000 -21% 01 Jul 2023 30 Sep 2023 10-Q 13 Dec 2024 2024 Q3
Q2 2023 $6,469,000 $1,525,000 -$305,000 -17% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $6,774,000 $1,458,000 -$390,000 -21% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $7,164,000 $1,736,000 -$223,000 -11% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $7,387,000 $1,750,000 -$120,000 -6.4% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $7,507,000 $1,830,000 +$219,000 +14% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $7,288,000 $1,848,000 +$57,000 +3.2% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $7,231,000 $1,959,000 +$591,000 +43% 01 Oct 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
Q3 2021 $6,640,000 $1,870,000 +$365,000 +24% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $6,275,000 $1,611,000 +$158,000 +11% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $6,117,000 $1,791,000 +$581,000 +48% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $5,536,000 $1,368,000 +$562,000 +70% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $4,974,000 $1,505,000 +$985,000 +189% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $3,989,000 $1,453,000 +$888,000 +157% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $3,101,000 $1,210,000 +$711,000 +142% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $2,390,000 $806,000 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q3 2019 $520,000 +$300,000 +136% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $565,000 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $499,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q3 2018 $220,000 01 Jul 2018 30 Sep 2018 10-Q 10 Dec 2019 2019 Q3

Galera Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,545,000 -$3,015,000 -54% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $5,560,000 -$1,604,000 -22% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $7,164,000 -$67,000 -0.93% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $7,231,000 +$1,695,000 +31% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
2020 $5,536,000 +$3,146,000 +132% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $2,390,000 +$1,525,000 +176% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $865,000 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.